



August 31, 2017

Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS) today announced that the Company will participate in three upcoming investor conferences in September:

┆ Citi 12th Annual Biotech Conference

- ┆ Chris Haqq, M.D., Ph.D., the Company's Executive Vice President of Research and Development and Chief Scientific Officer, will attend Citi's 12th Annual Biotech Conference on Thursday, September 7th, 2017. The conference will be held at the Mandarin Oriental Hotel in Boston, MA.

┆ Morgan Stanley 15th Annual Global Healthcare Conference

- ┆ Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will participate in a fireside chat discussion on Monday, September 11, 2017 at 4:15 p.m. EDT. The conference will be held at the Grand Hyatt Hotel in New York, NY.

┆ Cantor Fitzgerald 2017 Global Healthcare Conference

- ┆ John Craighead, Ph.D., the Company's Vice President of Investor Relations and Corporate Communications, will present a corporate overview on Tuesday, September 26, 2017 at 4:35 p.m. EDT. The Conference will be held at the InterContinental New York Barclay Hotel in New York, NY.

Live webcasts of the presentations at the Morgan Stanley and Cantor Fitzgerald healthcare conferences will be available by visiting the Investors section of the Atara website at www.atarabio.com. Archived replays of the webcasts will be available on the Company's website for 14 days following each presentation.

About Atara Biotherapeutics, Inc.

[Atara Biotherapeutics, Inc. \(@Atarabio\)](http://www.atarabio.com) is a leading cell therapy company developing novel treatments for patients with cancer and autoimmune diseases. The Company's "off-the-shelf", or allogeneic, T-cells are engineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Atara's most advanced T-cell immunotherapy in development, ATA129, is being developed for the treatment of cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV-PTLD), as well as other EBV positive hematologic and solid tumors including nasopharyngeal carcinoma (NPC). Phase 3 studies of ATA129 in EBV-PTLD following a hematopoietic cell transplant (HCT) or solid organ transplant (SOT) are expected to start in 2017, and a Phase 1/2 study of ATA129 in combination with Merck's anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with platinum-resistant or recurrent EBV-associated NPC is planned for 2018. ATA129 is also available to eligible patients with EBV-positive tumors through an ongoing multicenter expanded access protocol (EAP) clinical study. Atara expects to submit ATA129 for conditional marketing authorization in EBV-PTLD following HCT in the EU in 2018. ATA188, the Company's next generation T-cell immunotherapy for autoimmune diseases, selectively targets specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). A Phase 1 clinical study of autologous ATA188 in progressive forms of MS is ongoing, and a Phase 1 allogeneic ATA188 clinical study is expected to begin in the second half of 2017. Atara's clinical pipeline also includes ATA520 targeting Wilms Tumor 1 (WT1) and ATA230 directed against cytomegalovirus (CMV).

INVESTOR & MEDIA CONTACTS:

Investors:

John Craighead, Atara Biotherapeutics
650-491-5806
jcraighead@atarabio.com

Steve Klass, Burns McClellan
212-213-0006 x331

sklass@burnsmc.com

Media:

Justin Jackson, Burns McClellan

212-213-0006 x327

jjackson@burnsmc.com